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been identiﬁed in some ASD individuals, and is believed to be a key
gene involved in the behavioral phenotypes associated with 22q13 de-
letion syndrome (DS) (Durand et al., 2007; Harony-Nicolas et al., 2015).
SHANK3 haploinsufﬁcient neurons derived from patients with 22q13DS
display decreased glutamatergic transmission, which can be rescued by
a SHANK3 cDNA expression vector (Shcheglovitov et al., 2013). Similar-Induced pluripotent
Neuron
Screening
Shank3One of the primary obstacles facing researchers interested in autism
spectrum disorders (ASD) and other neuropsychiatric disorders is the
lack of direct access to live brain tissue. Animal models can be used as
a surrogate. However, data from the mouse and human ENCODE pro-
jects show substantial differences in regulatory domains,which suggests
that some unique pathophysiological features may exist in humans, and
that novel pharmacotherapies may not necessarily work in both species
(Kavanagh et al., 2013; Yue et al., 2014). However, the introduction of
induced pluripotent stem (iPS) cell technology has provided a promising
platform for disease modeling and drug screening that addresses these
obstacles (Brennand et al., 2011; Pedrosa et al., 2011; Zhao et al., 2012).
The challenge of developing effective pharmacotherapies for ASD is
also limited by our incomplete understanding of its etiology, aswell as ge-
netic and clinical heterogeneity. However, despite the complex genetic
underpinning of ASD, the clinical phenotype can be attributed to a distinct
genetic abnormality in a signiﬁcant proportion of patients (Persico and
Napolioni, 2013). This subgroup of ASD individuals can be a helpful re-
source for developing iPS cell-derived neurons to identify dysfunctional
underlying biological pathways, aswell as for the development of person-
alized therapeutic interventions targeting speciﬁc genetic abnormalities.
One such gene is SHANK3, one of several ASD risk genes that code for
synaptic proteins. SHANK3 is a scaffolding protein that helps form the
post-synaptic density (PSD), which plays a critical role in regulating016.05.032.
achman).
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ly, autistic phenotypes in adult mice can be rescued after restoring
SHANK3 expression (Mei et al., 2016).
In light of the precedingﬁndings, the study byDarville and colleagues
(Darville et al., 2016) is timely. They explored the therapeutic potential
of more than 200 pharmacological agents, using neurons differentiated
from iPS cells derived from ASD individuals heterozygous for SHANK3
null mutations. Darville et al. applied a comprehensive step-wise ap-
proach to identify potentially effective compounds. Using a qPCR-based
high throughput screening (HTS) method, they quantiﬁed the relative
expression of SHANK3 after treating day-14 neurons with the test com-
pounds, some of which were FDA-approved psychotropic drugs.
The authors found six compounds that increased SHANK3mRNA in a
concentration-dependentmanner, of which three were validated at the
protein level: lithium, valproic acid (VPA), and ﬂuoxetine. They per-
formed a quantitative immunostaining analysis of synapses using pre-
synaptic and post-synaptic neuronal markers. Only neurons treated
with lithium and VPA showed evidence of staining for all the synaptic
markers - indicative of increased SHANK3 activity. Recording spontane-
ous calcium oscillations (SCO) in the neurons at a later stage revealed
that only lithiumand VPA increased their intensity and frequency. Tran-
scriptome analysis demonstrated that, compared to VPA, lithium targets
a narrower range of neuronal and synaptic genes, which perhaps could
translate into a more speciﬁc and safer treatment.
To identify molecular pathways that lithium and VPA possibly share
in their effect on SHANK3 expression, the authors hypothesized that
Glycogen Synthase Kinase 3 (GSK3) and/or class I Histone Deacetylase
(HDAC) could be the possible common targets. Treating the iPS cell-de-
rived neurons with two agents, CHIR99021 (a selective GSK3 inhibitor)
and Trichostatin A (a selective HDAC inhibitor) revealed that only the
latter agent increased SHANK3mRNA. Similarly, a pathway enrichment
analysis on genes regulated by lithium and VPA showed that histone
modiﬁcations, but not GSK3 per se, is themore likelymechanism shared
by these two drugs in the upregulation of SHANK3.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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embryonic stem cell (hESC) line as a control. When studying epige-
netic phenomena in iPS cells, such as involvement of HDAC in a drug
response, it is important to consider the fact that epigenetic differ-
ences may exist in iPS cell lines related to reprogramming and cell
of origin, which can theoretically affect experimental ﬁndings.
Thus, the observation by Darville et al. that the response to lithium
and valproate was the same in the hESC line and iPS cells is
signiﬁcant.
Finally, the study is complemented by a trial of lithium administered
to one of the ASD patients whose cells were used in the screening study.
The authors reported some improvement in the clinical presentation
after one year, based on several quantitative scales. However, worsen-
ing of some measures (e.g., ADHD symptoms) was also observed. The
authors appropriately caution that at this stage, the use of lithium to
treat patients with SHANK3 haploinsufﬁciency is premature. Neverthe-
less, this study is an interesting illustration of the potential use of neuro-
nal cells derived from iPS cells for high-throughput drug screening, and
the development of personalized medicine for complex neuropsychiat-
ric disorders.References
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